Natera, Inc. NTRA
Composite 48/100; the shares have moved about 57% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 8/100 — a strong mark against it.
Growth ranks 89/100 — a strong point in its favour. Momentum ranks 86/100 — a strong point in its favour. Balance-sheet strength ranks 66/100 — a moderate point in its favour.
Valuation ranks 8/100 — a strong mark against it. Quality ranks 18/100 — a strong mark against it.
What the company does Natera develops and sells molecular diagnostics including Signatera (ctDNA cancer monitoring), Panorama (NIPT), and Prospera (organ transplant rejection testing). Its tests target cancer recurrence, hereditary conditions, and prenatal screening, leveraging proprietary cloud-based software and genomic profiling.
Key financials Natera reports gross margin of 65.1% but negative operating (-12.4%) and net (-9.0%) margins. Revenue grew 38.8% YoY, while EPS growth is 0%. ROE is -15.0%, ROA -9.1%, and ROCE -13.5%. Debt/equity is 0.14 with a current ratio of 2.96.
Stock health Momentum is strong: +28.52% over 3m, +14.46% over 6m, and +87.96% over 12m. RSI(14) is 53.80. SideraVIA scores Quality 20.7 (poor), Growth 62.4, Strength 66.7, Valuation 44.9, and Momentum 79.5.
Price vs fair value The stock trades at a **PREMIUM** of 6.76% versus the analyst 12-month target of 282.86. - Simply Wall St flags NTRA as overvalued despite Signatera optimism (Simply Wall St). - StockStory questions the stock’s popularity and suggests reconsideration (StockStory). - Valuation percentile of 44.9/100 indicates rich pricing relative to peers (SideraVIA). - Negative profitability metrics (ROE -15.0%, net margin -9.0%) contrast with high revenue growth (38.8%) (Key Financials).
Looking forward Analysts project a 12-month target implying ~7% upside, but quality and valuation concerns persist. Growth in MRD and NIPT markets supports long-term optimism, though profitability remains a key monitorable.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.